[Corrigendum] Beneficial effects of sulfonamide‑based gallates on osteoblasts <em>in vitro</em>

Huang,Li; Jin,Pan; Lin,Xiao; Lin,Cuiwu; Zheng,Li; Zhao,Jinmin

doi:10.3892/mmr.2021.12152

July-2021 Volume 24 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2021 Volume 24 Issue 1

Full Size Image

Correction Open Access

[Corrigendum] Beneficial effects of sulfonamide‑based gallates on osteoblasts in vitro

Authors:
- Li Huang
- Pan Jin
- Xiao Lin
- Cuiwu Lin
- Li Zheng
- Jinmin Zhao
View Affiliations / Copyright

Affiliations: Guangxi Engineering Center for Biomaterials for Tissue and Organ Regeneration, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, School of Chemistry and Chemical Engineering, Guangxi University, Nanning, Guangxi 530004, P.R. China

Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Article Number: 513
|
Published online on: May 13, 2021

https://doi.org/10.3892/mmr.2021.12152
Expand metrics +

Article

Mol Med Rep 15: [Related article:] 1149-1156, 2017; DOI: 10.3892/mmr.2017.6142

Following the publication of the above article, an interested reader drew to the authors' attention that three figures in their paper (namely Figs. 2, 4 and 5) appeared to feature panels containing overlapping data. The authors re-examined their original data, and realized that they had made inadvertent errors in the compilation of the data in these figures; specifically, the data shown in the panels for Fig. 2G, Fig. 4C, D and I, and Fig. 5E and I had been selected incorrectly.

Figure 2.

Fluorescein diacetate/propidium iodide staining of osteoblasts cultured with various concentrations of JEZ-C over time. Viable cells were stained green and dead cells were stained red. Staining of osteoblasts treated with (A) 0 µg/ml, (B) 6.25×10−3 µg/ml, (C) 6.25×10−2 µg/ml and (D) 6.25×10−1 µg/ml JEZ-C at day 2. Staining of osteoblasts treated with (E) 0 µg/ml, (F) 6.25×10−3 µg/ml, (G) 6.25×10−2 µg/ml and (H) 6.25×10−1 µg/ml JEZ-C at day 4. Staining of osteoblasts treated with (I) 0 µg/ml, (J) 6.25×10−3 µg/ml, (K) 6.25×10−2 µg/ml and (L) 6.25×10−1 µg/ml JEZ-C at day 6. Staining was markedly strengthened over time in all groups. Cells treated with JEZ-C exhibited stronger staining compared with the control group, particularly at 6.25×10−2 µg/ml. Scale bar=200 µm. (M) Relative cell number of osteoblasts treated with various concentrations (0, 6.25×10−3, 6.25×10−2 and 6.25×10−1 µg/ml) of JEZ-C. Cell proliferation was higher in the 6.25×10−2 µg/ml group compared with in the other groups. Data are presented as the mean ± standard deviation (n=9). *P<0.05 vs. JEZ-C, 0 µg/ml; #P<0.05 vs. JEZ-C, 6.25×10−3 µg/ml..

Figure 4.

ALP staining of osteoblasts treated with various concentrations of JEZ-C. ALP staining of osteoblasts treated with (A) 0 µg/ml, (B) 6.25×10−3 µg/ml, (C) 6.25×10−2 µg/ml and (D) 6.25×10−1 µg/ml JEZ-C on day 2. ALP staining of osteoblasts treated with (E) 0 µg/ml, (F) 6.25×10−3 µg/ml, (G) 6.25×10−2 µg/ml and (H) 6.25×10−1 µg/ml JEZ-C on day 4. ALP staining of osteoblasts treated with (I) 0 µg/ml, (J) 6.25×10−3 µg/ml, (K) 6.25×10−2 µg/ml and (L) 6.25×10−1 µg/ml JEZ-C on day 6. Scale bar=100 µm. (M) Time-course of ALP activity of osteoblasts treated with various concentrations (0, 6.25×10−3, 6.25×10−2 and 6.25×10−1 µg/ml) of JEZ-C. Relative ALP activity (units/mg protein) was expressed as mean ± standard deviation (n=3). ALP activity in the 6.25×10−2 µg/ml JEZ-C group was significantly higher than in the other groups. *P<0.05 vs. JEZ-C, 0 µg/ml; #P<0.05 vs. JEZ-C, 6.25×10−3 µg/ml. ALP, alkaline phosphatase.

Figure 5.

Alizarin red staining of osteoblasts cultured with various concentrations of JEZ-C over time. Staining of osteoblasts treated with (A) 0 µg/ml, (B) 6.25×10−3 µg/ml, (C) 6.25×10−2 µg/ml and (D) 6.25×10−1 µg/ml JEZ-C on day 2. Staining of osteoblasts treated with (E) 0 µg/ml, (F) 6.25×10−3 µg/ml, (G) 6.25×10−2 µg/ml and (H) 6.25×10−1 µg/ml JEZ-C on day 4. Staining of osteoblasts treated with (I) 0 µg/ml, (J) 6.25×10−3 µg/ml, (K) 6.25×10−2 µg/ml and (L) 6.25×10−1 µg/ml JEZ-C on day 6. Scale bar=100 µm. Staining was markedly strengthened over time in all groups. Cells treated with JEZ-C exhibited stronger staining compared with the control, particularly when treated with 6.25×10−2 µg/ml JEZ-C.

The corrected versions of Figs. 2, 4 and 5 are shown below and on the next page. All the authors approve of this corrigendum, and are grateful of the Editor of Molecular Medicine Reports for granting them the opportunity to publish this corrigendum. Furthermore, they regret that these errors were introduced into the paper, even though they did not substantially alter any of the major conclusions reported in the paper, and apologize to the readership for any inconvenience caused.